ABC | Volume 112, Nº3, Março 2019

Atualização Atualização da Diretriz em Cardiologia do Esporte e do Exercício da Sociedade Brasileira de Cardiologia e da Sociedade Brasileira de Medicina do Exercício e Esporte – 2019 Arq Bras Cardiol. 2019; 112(3):326-368 160. Costa HS, Nunes MC, Souza AC, Lima MM, Carneiro RB, Sousa GR, et al. Exercise-induced ventricular arrhythmias and vagal dysfunction in Chagas disease patients with no apparent cardiac involvement. Rev Soc Bras Med Trop. 2015;48(2):175-80. 161. Tassi EM, Continentino MA, do Nascimento EM, Pereira BB, Pedrosa RC. Relationship between fibrosis and ventricular arrhythmias in Chagas heart diseasewithoutventriculardysfunction.ArqBrasCardiol.2014;102(5):456- 64. 162. Matos LD, Azevedo LF, Brum PC, Sosa EA, Martinelli M, Negrão CE. Long distance runner with dilated cardiomyopathy and excellent performance. Arq Bras Cardiol. 2011;96(1):e3-6. 163. Panhuyzen-GoedkoopNM,WildeAA.Athleteswithchannelopathymaybe eligible to play. NethHeart J. 2018;26(3):146-53. 164. Garg P, Garg V, Shrestha R, Sanguinetti MC, Kamp TJ, Wu JC. Human induced pluripotent stem cell-derived cardiomyocytes as models for cardiac channelopathies: a primer for non-electrophysiologists. Circ Res. 2018;123(2):224-43. 165. DespaS,VigmondE.Fromsinglemyocytetowholeheart:theintricatedance of electrophysiology andmodeling. Circ Res. 2016;118(2):184-6. 166. Fonseca DJ, Vaz da Silva MJ. Cardiac channelopathies: the role of sodium channel mutations. Rev Port Cardiol. 2018;37(2):179-99. 167. Lazzerini PE, Capecchi PL, Laghi-Pasini F, Boutjdir M. Autoimmune channelopathies as a novel mechanism in cardiac arrhythmias. Nat Rev Cardiol. 2017;14(9):521-35. 168. Etheridge SP, Saarel EV, Martinez MW. Exercise participation and shared decision-making in patients with inherited channelopathies and cardiomyopathies. Heart Rhythm. 2018;15(6):915-20. 169. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J. 1957;54(1):59-68. 170. Schwartz PJ, Crotti L, Insolia R. Long-QT syndrome: from genetics to management. Circ ArrhythmElectrophysiol. 2012;5(4):868-77. Erratum in: Circ ArrhythmElectrophysiol. 2012;5(6):e119-20. 171. Garcia-EliasA,BenitoB.Ionchanneldisordersandsuddencardiacdeath.Int J Mol Sci. 2018;19(3). pii: E692. 172. Mazzanti A, Maragna R, Vacanti G, Monteforte N, Bloise R, MarinoM, et al. Interplay between genetic substrate, QTc duration, and arrhythmia risk in patients with longQT syndrome. J AmColl Cardiol. 2018;71(15):1663-71. 173. Moreno C, Oliveras A, Bartolucci C, Muñoz C, de la Cruz A, Peraza DA, et al. D242N, a KV7.1 LQTS mutation uncovers a key residue for IKs voltage dependence. J Mol Cell Cardiol. 2017 Sep;110:61-69. 174. LiuL,TianJ,LuC,ChenX,FuY,XuB,etal.ElectrophysiologicalCharacteristics of the LQT2 Syndrome Mutation KCNH2-G572S and Regulation by Accessory Protein KCNE2. Front Physiol. 2016Dec 27;7:650. 175. Jackson HA, Accili EA. Evolutionary analyses of KCNQ1 and HERG voltagegated potassium channel sequences reveal location-specific susceptibility and augmented chemical severities of arrhythmogenic mutations. BMC Evol Biol. 2008 Jun 30;8:188. 176. Zimmer T, Surber R. SCN5A channelopathies--an update onmutations and mechanisms. Prog BiophysMol Biol. 2008;98(2-3):120-36. 177. Wilde AA, Moss AJ, Kaufman ES, ShimizuW, Peterson DR, Benhorin J, et al. Clinical aspects of type 3 long-QT syndrome: an International Multicenter Study. Circulation. 2016;134(12):872-82. 178. PrioriSG,SchwartzPJ,NapolitanoC,BloiseR,RonchettiE,GrilloM,etal.Risk stratificationinthelong-QTsyndrome.NEnglJMed.2003;348(19):1866-74. 179. AzizPF,SweetenT,VogelRL,BonneyWJ,Henderson J,PatelAR,etal.Sports participationingenotypepositivechildrenwithlongQTsyndrome.JACCClin Electrophysiol. 2015;1(1-2):62-70. 180. Ackerman MJ, Zipes DP, Kovacs RJ, Maron BJ. Eligibility and disqualification recommendationsforcompetitiveathleteswithcardiovascularabnormalities: task force 10: the cardiac channelopathies: a scientific statement from the American Heart Association and American College of Cardiology. J AmColl Cardiol. 2015;66(21):2424-8. 181. Steinberg C. Diagnosis and clinical management of long-QT syndrome. Curr Opin Cardiol. 2018;33(1):31-41. 182. Ahn J, Kim HJ, Choi JI, Lee KN, Shim J, Ahn HS, et al. Effectiveness of beta-blockers depending on the genotype of congenital long-QT syndrome: a meta-analysis. PLoS One. 2017;12(10):e0185680. 183. Pérez-Riera AR, Barbosa-Barros R, Daminello Raimundo R, da Costa de Rezende Barbosa MP, Esposito Sorpreso IC, de Abreu LC. The congenital long QT syndrome Type 3: an update. Indian Pacing Electrophysiol J. 2018;18(1):25-35. 184. Shah SR, Park K. Long QT syndrome: a comprehensive review of the literature and current evidence. Curr Probl Cardiol. 2018 May 10. pii: S0146-2806(18)30051-3. 185. Bjerregaard P. Diagnosis and management of short QT syndrome. Heart Rhythm. 2018;15(8):1261-7. 186. Sharma S, Drezner JA, Baggish A, Papadakis M, Wilson MG, Prutkin JM, et al. International recommendations for electrocardiographic interpretation in athletes. J Am Coll Cardiol. 2017;69(8):1057-75. 187. Cubeddu LX. Drug-induced inhibition and trafficking disruption of ion channels: pathogenesis of QT abnormalities and drug-induced fatal arrhythmias. Curr Cardiol Rev. 2016;12(2):141-54. 188. El-Battrawy I, LanH, Cyganek L, Zhao Z, Li X, Buljubasic F, et al. Modeling short QT syndrome using human-induced pluripotent stem cell-derived cardiomyocytes. J Am Heart Assoc. 2018;7(7). pii: e007394. 189. Gaita F, Giustetto C, Bianchi F, Schimpf R, Haissaguerre M, Calò L, et al. Short QT syndrome: pharmacological treatment. J Am Coll Cardiol. 2004;43(8):1494-9. 190. Mondoly P, Cardin C, Rollin A, Duparc A, Maury P. Use of a subcutaneous ICD in a patient with short QT syndrome. Clin Case Rep. 2015;4(1):35-8. 191. Schimpf R, Wolpert C, Bianchi F, Giustetto C, Gaita F, Bauersfeld U, et al. Congenital short QT syndrome and implantable cardioverter defibrillator treatment: inherent risk for inappropriate shock delivery. J Cardiovasc Electrophysiol. 2003;14(12):1273-7. 192. Gourraud JB, Barc J, Thollet A, Le Marec H, Probst V. Brugada syndrome: diagnosis, risk stratification and management. Arch Cardiovasc Dis. 2017;110(3):188-95. 193. Argenziano M, Antzelevitch C. Recent advances in the treatment of Brugada syndrome. Expert Rev Cardiovasc Ther. 2018;16(6):387-404. 194. Antzelevitch C, Yan GX, Ackerman MJ, Borggrefe M, Corrado D, Guo J, et al. J-Wave syndromes expert consensus conference report: emerging concepts and gaps in knowledge. Europace. 2017;19(4):665-694. 195. Ghouse J, Have CT, Skov MW, Andreasen L, Ahlberg G, Nielsen JB, et al. Numerous Brugada syndrome-associated genetic variants have no effect on J-point elevation, syncope susceptibility, malignant cardiac arrhythmia, and all-cause mortality. Genet Med. 2017;19(5):521-8. 196. Gray B, Hasdemir C, Ingles J, Aiba T, Makita N, Probst V, et al. Lack of genotype-phenotype correlation in Brugada syndrome and sudden arrhythmic death syndrome families with reported pathogenic SCN1B variants. Heart Rhythm. 2018;15(7):1051-1057. 197. Wu W, Tian L, Ke J, Sun Y, Wu R, Zhu J, et al. Risk factors for cardiac events in patients with Brugada syndrome: a PRISMA- compliant meta-analysis and systematic review. Medicine (Baltimore). 2016;95(30):e4214. 198. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, et al. Brugada syndrome: report of the second consensus conference. Heart Rhythm. 2005;2(4):429-40. 199. Pérez-Riera AR, Barbosa-Barros R, de Rezende Barbosa MP, Daminello- Raimundo R, de Lucca AA Jr, de Abreu LC. Catecholaminergic polymorphic ventricular tachycardia, an update. Ann Noninvasive Electrocardiol. 2018;23(4):e12512. 200. Kannankeril PJ, Moore JP, Cerrone M, Priori SG, Kertesz NJ, Ro PS, et al. Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia: a randomized clinical trial. JAMA Cardiol. 2017;2(7):759-66. 365